Subject(s)
Amphetamine , Cocaine , Hallucinogens , Narcotics , Solvents , Substance-Related Disorders/prevention & control , Acquired Immunodeficiency Syndrome/etiology , Acquired Immunodeficiency Syndrome/prevention & control , Humans , Incidence , Poland/epidemiology , Substance-Related Disorders/complications , Substance-Related Disorders/epidemiologyABSTRACT
Therapeutic effects of TMZ treatment were evaluated in 31 patients with atrio-cochlear disorders caused by an insufficiency of cerebral circulation. It was found that the results of vestibular or cochlear disorders remission was dependent on the time interval between the onset of symptoms and the beginning of trimetazidine therapy. The best results were also found in patients suffering from atrio-cochlear disorders lasting not longer than two years and due to arterial hypertension or cerebral basilar artery insufficiency.
Subject(s)
Cerebrovascular Disorders/drug therapy , Cochlear Diseases/drug therapy , Trimetazidine/therapeutic use , Vestibular Diseases/drug therapy , Cerebrovascular Disorders/complications , Cochlear Diseases/etiology , Female , Humans , Male , Middle Aged , Vestibular Diseases/etiologyABSTRACT
The investigations were aimed at the objective evaluating of trimetazidine efficacy in the treatment of 30 patients with arterial hypertension and ischemic heart disease carried out in non-invasive manner. It was found that trimetazidine complies with several requirements for the effective drug administered to the patients with hypertension associated with ischemic heart disease as it: (a) reduces peripheral resistance and exerts favourable effect on the walls tonus of larger arteries; (b) lowers specifically post-exercise arterial pressure and improves resting arterial pressure; (c) reduces demand for oxygen; (d) is safe, and well tolerated by 83% of the treated patients in daily dose of 60 mg.
Subject(s)
Blood Pressure/drug effects , Coronary Disease/drug therapy , Hypertension/drug therapy , Trimetazidine/therapeutic use , Adult , Aged , Blood Pressure/physiology , Coronary Disease/complications , Coronary Disease/physiopathology , Coronary Vessels/drug effects , Coronary Vessels/physiopathology , Double-Blind Method , Female , Humans , Hypertension/complications , Hypertension/physiopathology , Male , Middle Aged , Placebos , Vascular Resistance/drug effects , Vascular Resistance/physiologySubject(s)
Contraceptives, Oral, Combined/pharmacology , Estradiol Congeners/pharmacology , Progesterone Congeners/pharmacology , Uterus/drug effects , Animals , Estradiol Congeners/administration & dosage , Female , Organ Size/drug effects , Progesterone Congeners/administration & dosage , Rats , Rats, Inbred StrainsSubject(s)
Alanine Transaminase/metabolism , Aspartate Aminotransferases/metabolism , Catechin/therapeutic use , Creatine Kinase/metabolism , Diabetes Mellitus, Experimental/enzymology , Hypoglycemic Agents/therapeutic use , Myocardium/enzymology , Alanine Transaminase/blood , Animals , Aspartate Aminotransferases/blood , Diabetes Mellitus, Experimental/drug therapy , Rats , StreptozocinABSTRACT
Enkephalin-hydrolytic activity was evaluated in cerebral and cardiac tissue of Wistar rats with experimental streptozotocin-induced diabetes by comparison of the degree of amino acid cleavage from leu-enkephalin in vitro. Ninety days after induction of diabetes the enkephalin-hydrolytic activity was elevated in the cerebral tissue but depressed in the cardiac muscle.
